Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)

Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q), Published online: 18 December 2017; doi:10.1038/s41408-017-0017-8Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research

Related Links:

Publication date: Available online 10 October 2018Source: Cancer GeneticsAuthor(s): Rashmi Kanagal-Shamanna, Jennelle C. Hodge, Tracy Tucker, Shashi Shetty, Ashwini Yenamandra, Amanda Dixon-McIver, Christine Bryke, Emma Huxley, Patrick A. Lennon, Gordana Raca, Xinjie Xu, Sally Jeffries, Fabiola Quintero-Rivera, Patricia T. Greipp, Marilyn L. Slovak, M. Anwar Iqbal, Min FangAbstractMultiple studies have demonstrated the utility of chromosomal microarray (CMA) testing to identify clinically significant copy number alterations (CNAs) and copy-neutral loss-of-heterozygosity (CN-LOH) in myeloid malignancies. However, guidelines...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
Genes, Chromosomes and Cancer,Volume 0, Issue ja, -Not available-.
Source: Genes, Chromosomes and Cancer - Category: Cancer & Oncology Authors: Source Type: research
EAST SETAUKET, NY , Oct. 09, 2018 -- (Healthcare Sales &Marketing Network) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety and therapeutic benefit of Lixte’s... Biopharmaceuticals, Oncology, FDA Lixte Biotechnology, protein phosphatases, Myelodysplastic Syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Cancer, EarlyView.
Source: Cancer - Category: Cancer & Oncology Authors: Source Type: research
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
ROCHESTER, Minn. ? Researchers at Mayo Clinic have developed a new genetics-based prognostic tool for myelodysplastic syndrome. Their findings are published in the October print issue of Mayo Clinic Proceedings. ?Myelodysplastic syndrome is one of the most frequent blood cancers affecting the elderly with annual incidence exceeding 50 cases per 100,000 in people 65 years [...]
Source: Mayo Clinic Research News - Category: Research Source Type: news
In conclusion, our study suggests that targeting NFE2L2 in combination with conventional chemotherapy could pave the way for future high-risk myelodysplastic syndromes therapy. PMID: 30262569 [PubMed - as supplied by publisher]
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
AbstractPurpose of ReviewTo review the diagnosis of individuals with hereditary hematopoietic malignancies (HHMs) that predispose to myelodysplastic syndrome and acute myeloid leukemia, barriers to HHM diagnosis, and unaddressed questions and controversies within the HHM field.Recent FindingsPathogenic germline mutations in approximately a dozen genes predispose to HHMs, and many more genes are likely to be involved. Many of these HHM genes have only been identified recently. HHM phenotypes are diverse, but may be categorized as “purely” myeloid syndromes, syndromes with abnormal platelet number/function, and H...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Genes, Chromosomes and Cancer, EarlyView.
Source: Genes, Chromosomes and Cancer - Category: Cancer & Oncology Authors: Source Type: research
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q), Published online: 21 September 2018; doi:10.1038/s41408-018-0126-zThe impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Myelodysplastic Syndrome